title: Developing Extracellular Matrix Technology to Treat Retinal or Optic Nerve Injury(1,2,3).
abstract: Adult mammalian CNS neurons often degenerate after injury, leading to lost neurologic functions. In the visual system, retinal or optic nerve injury often leads to retinal ganglion cell axon degeneration and irreversible vision loss. CNS axon degeneration is increasingly linked to the innate immune response to injury, which leads to tissue-destructive inflammation and scarring. Extracellular matrix (ECM) technology can reduce inflammation, while increasing functional tissue remodeling, over scarring, in various tissues and organs, including the peripheral nervous system. However, applying ECM technology to CNS injuries has been limited and virtually unstudied in the visual system. Here we discuss advances in deriving fetal CNS-specific ECMs, like fetal porcine brain, retina, and optic nerve, and fetal non-CNS-specific ECMs, like fetal urinary bladder, and the potential for using tissue-specific ECMs to treat retinal or optic nerve injuries in two platforms. The first platform is an ECM hydrogel that can be administered as a retrobulbar, periocular, or even intraocular injection. The second platform is an ECM hydrogel and polymer "biohybrid" sheet that can be readily shaped and wrapped around a nerve. Both platforms can be tuned mechanically and biochemically to deliver factors like neurotrophins, immunotherapeutics, or stem cells. Since clinical CNS therapies often use general anti-inflammatory agents, which can reduce tissue-destructive inflammation but also suppress tissue-reparative immune system functions, tissue-specific, ECM-based devices may fill an important need by providing naturally derived, biocompatible, and highly translatable platforms that can modulate the innate immune response to promote a positive functional outcome.
authors.affiliation: Department of Ophthalmology, School of Medicine, University of Pittsburgh , Pittsburgh, Pennsylvania 15216 ; McGowan Institute for Regenerative Medicine, University of Pittsburgh , Pittsburgh, Pennsylvania 15219.
authors.forename: Tanchen
authors.initials: T
authors.lastname: Ren
authors.affiliation: Department of Ophthalmology, School of Medicine, University of Pittsburgh , Pittsburgh, Pennsylvania 15216 ; McGowan Institute for Regenerative Medicine, University of Pittsburgh , Pittsburgh, Pennsylvania 15219 ; Department of Bioengineering, Swanson School of Engineering, University of Pittsburgh , Pittsburgh, Pennsylvania 15260.
authors.forename: Yolandi
authors.initials: Y
authors.lastname: van der Merwe
authors.affiliation: Department of Ophthalmology, School of Medicine, University of Pittsburgh , Pittsburgh, Pennsylvania 15216 ; McGowan Institute for Regenerative Medicine, University of Pittsburgh , Pittsburgh, Pennsylvania 15219 ; Center for Neuroscience, University of Pittsburgh , Pittsburgh, Pennsylvania 15216.
authors.forename: Michael B
authors.initials: MB
authors.lastname: Steketee
keywords: ECM; axon regeneration; immunotherapy; regenerative medicine; retinal ganglion cell